AI English summary of an SEC filing — figures as filed
Baxter International BAXBaxter said worldwide sales from continuing operations in Q3 2025 totaled approximately $2.84 billion, increasing 5% on a reported basis and 2% on an operational basis. U.S. sales from continuing operations totaled approximately $1.54 billion, increasing 3% on a reported basis and declining 1% on an operational basis.
Key points
AI summaryBaxter said worldwide sales from continuing operations in Q3 2025 totaled approximately $2.84 billion, increasing 5% on a reported basis and 2% on an operational basis. U.S. sales from continuing operations totaled approximately $1.54 billion, increasing 3% on a reported basis and declining 1% on an operational basis.
The company said net loss from continuing operations in Q3 2025 on a U.S. GAAP basis totaled ($51) million, or ($0.10) per diluted share, while adjusted diluted EPS from continuing operations was $0.69, increasing 41% over the prior year. Special items included certain tax matters.
Baxter said Medical Products & Therapies sales in Q3 2025 totaled approximately $1.33 billion, declining 1% on a reported basis, Healthcare Systems & Technologies sales totaled approximately $773 million, increasing 3%, and Pharmaceuticals sales totaled approximately $632 million, increasing 7%.
The company said it expects full-year 2025 sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% on an operational basis, and adjusted diluted EPS from continuing operations of $2.35 to $2.40. It said it expects adjusted diluted EPS from continuing operations in Q4 of $0.52 to $0.57.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q3 2025 Continuing Operations Sales and Regional Growth
Baxter said worldwide sales from continuing operations in Q3 2025 totaled approximately $2.84 billion, increasing 5% on a reported basis and 2% on an operational basis. U.S. sales from continuing operations totaled approximately $1.54 billion, increasing 3% on a reported basis and declining 1% on an operational basis.
Source · Based on the filing body and exhibits
Q3 GAAP Net Loss, Adjusted EPS and Tax Items
The company said net loss from continuing operations in Q3 2025 on a U.S. GAAP basis totaled ($51) million, or ($0.10) per diluted share, while adjusted diluted EPS from continuing operations was $0.69, increasing 41% over the prior year. Special items included certain tax matters.
Source · Based on the filing body and exhibits
Q3 Segment Sales
Baxter said Medical Products & Therapies sales in Q3 2025 totaled approximately $1.33 billion, declining 1% on a reported basis, Healthcare Systems & Technologies sales totaled approximately $773 million, increasing 3%, and Pharmaceuticals sales totaled approximately $632 million, increasing 7%.
Source · Based on the filing body and exhibits
Full-Year 2025 and Q4 Outlook
The company said it expects full-year 2025 sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% on an operational basis, and adjusted diluted EPS from continuing operations of $2.35 to $2.40. It said it expects adjusted diluted EPS from continuing operations in Q4 of $0.52 to $0.57.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…